| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers worldwide. The purpose of this study was to develop a new method for evaluating the degree of malignancy of ESCC and a novel therapeutic approach for ESCC focusing on chemokine network. Immunohistochemical analysis of the past surgical specimen revealed that positive expression of CXCL12-CXCR4, IL8-CXCR2, and CCL5-CCR5 were the independent prognostic factors as well as histological stage, and the number of expressing networks had correlation with poor prognosis. Secondly, we reported that the proliferative ability of ESCC overexpressing or exposed to above mentioned chemokine were significantly enhanced compared with wildtype cells in vitro. Third, the antagonists of chemokine receptors inhibited the tumor growth of ESCC in vivo. Taken together, chemokine network was not only a promising biomarker but also a novel molecular target for inhibiting ESCC proliferation.
|
